Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse

17 Apr 2025

Abstract excerpt

BACKGROUND: The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contributing to MM progression and relapse. Overexpression of the de novo DNA methyltransferase 3B (DNMT3B) in MM has been reported, correlating with poor prognosis. However, its exact role in MM cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40241199
DOI: 10.1186/s13046-025-03382-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapsePMID 40241199Read ↗

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity Read ↗

The Role of Epigenetics in the Development and Progression of Multiple MyelomaSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cellsSemantic proximity Read ↗

High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple MyelomaSemantic proximity Read ↗

Therapeutic Potential of PRMT1 as a Critical Survival Dependency Target in Multiple MyelomaSemantic proximity Read ↗

Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation InhibitorsSemantic proximity Read ↗

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSemantic proximity Read ↗

Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity Read ↗

Epigenetic Aberrations in Multiple MyelomaSemantic proximity Read ↗

Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.Semantic proximity Read ↗

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.